BDTX
NASDAQ · Biotechnology
Black Diamond Therapeutics I
$1.83
-0.05 (-2.66%)
Open$1.89
Previous Close$1.88
Day High$1.89
Day Low$1.81
52W High$4.94
52W Low$1.60
Volume—
Avg Volume684.8K
Market Cap108.01M
P/E Ratio—
EPS$-0.74
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,862.8% upside
Current
$1.83
$1.83
Target
$35.92
$35.92
$30.62
$35.92 avg
$44.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 69.50M | 26.85M | 24.30M |
| Net Income | 22.21M | 2.09M | 2.49M |
| Profit Margin | 32.0% | 7.8% | 10.3% |
| EBITDA | 12.76M | 3.87M | 3.57M |
| Free Cash Flow | — | 2.98M | 2.09M |
| Rev Growth | — | +10.3% | +9.4% |
| Debt/Equity | — | 0.41 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |